-
EP3970738
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3970738
| EP3970738 - BLOOD FACTOR MONITORING ASSAY AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 05.07.2024 | |
| Former | The application has been published Status updated on 18.02.2022 | Most recent event Tooltip | 14.06.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Bioverativ Therapeutics Inc. 225 Second Avenue Waltham, MA 02451 / US | [2022/12] | Inventor(s) | 01 /
Sommer, Jurg Wayland, MA 01778 / US | [2022/12] | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2022/12] | Application number, filing date | 20215649.3 | 25.07.2013 | [2022/12] | Priority number, date | US201261675713P | 25.07.2012 Original published format: US 201261675713 P | [2022/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3970738 | Date: | 23.03.2022 | Language: | EN | [2022/12] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.10.2021 | Classification | IPC: | A61K38/37, A61K38/36, C07K14/755 | [2022/12] | CPC: |
G01N33/86 (EP,US);
A61K38/4846 (EP,US);
C12Y304/21022 (EP,US);
G01N33/92 (EP,US);
G01N2333/755 (US);
G01N2333/9645 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] |
| Former [2022/12] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | BLUTFAKTORÜBERWACHUNGSTEST UND VERWENDUNGEN DAVON | [2022/12] | English: | BLOOD FACTOR MONITORING ASSAY AND USES THEREOF | [2022/12] | French: | ESSAI DE SURVEILLANCE DE FACTEUR SANGUIN ET UTILISATIONS DE CELUI-CI | [2022/12] | Examination procedure | 23.09.2022 | Amendment by applicant (claims and/or description) | 23.09.2022 | Examination requested [2022/44] | 23.09.2022 | Date on which the examining division has become responsible | Parent application(s) Tooltip | EP13823087.5 / EP2877202 | Fees paid | Renewal fee | 12.04.2021 | Renewal fee patent year 03 | 12.04.2021 | Renewal fee patent year 04 | 12.04.2021 | Renewal fee patent year 05 | 12.04.2021 | Renewal fee patent year 06 | 12.04.2021 | Renewal fee patent year 07 | 12.04.2021 | Renewal fee patent year 08 | 15.07.2021 | Renewal fee patent year 09 | 15.06.2022 | Renewal fee patent year 10 | 14.06.2023 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US5059525 (BARTL KNUT [DE], et al) [Y] 1-11* the whole document *; | [Y]WO2004102202 (NAT INST BIOLOGICAL STANDARDS & CONTROL [GB], et al) [Y] 1-11 * pages 4,5; figure 4; examples 1-3 *; | [XP]WO2013016454 (BIOGEN IDEC HEMOPHILIA INC [US], et al) [XP] 1-11 * figures 6,7; examples 2,3; tables 2,3 *; | [Y] - J. AHNSTROM ET AL, "A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia", HAEMOPHILIA, GB, (20041101), vol. 10, no. 6, doi:10.1111/j.1365-2516.2004.01036.x, ISSN 1351-8216, pages 689 - 697, XP055262996 [Y] 1-11 * the whole document * DOI: http://dx.doi.org/10.1111/j.1365-2516.2004.01036.x | [Y] - P. W. COLLINS ET AL, "Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia", HAEMOPHILIA, GB, (20110122), vol. 17, no. 1, doi:10.1111/j.1365-2516.2010.02370.x, ISSN 1351-8216, pages 2 - 10, XP055263023 [Y] 1-11 * the whole document * DOI: http://dx.doi.org/10.1111/j.1365-2516.2010.02370.x |